Cross-protection between different influenza A subtypes (heterosubtypic immunity) has been shown in animals after infection with wild-type influenza and administration of some types of influenza vaccines. However, data regarding protective heterosubtypic immunity in humans are limited. The aim of this analysis is to examine data from unvaccinated subjects followed in multiyear, culture-confirmed vaccine efficacy studies for evidence of heterosubtypic protection.
Background and aims:
Cross-protection between different influenza A subtypes (heterosubtypic immunity) has been shown in animals after infection with wild-type influenza and administration of some types of influenza vaccines. However, data regarding protective heterosubtypic immunity in humans are limited. The aim of this analysis is to examine data from unvaccinated subjects followed in multiyear, culture-confirmed vaccine efficacy studies for evidence of heterosubtypic protection.
Methods:
Four 2-year studies of children aged 6-71 months were analyzed. Placebo recipients were separated into cohorts based on whether the subject experienced culture-confirmed influenza illness in year 1. The incidence of influenza illness by subtype per cohort was calculated for year 2. Subjects with confirmed illness in year 1 were compared with subjects with no evidence of any influenza illness in year 1.
Results:
Conclusions: In this analysis of the 2-year incidence of culture-confirmed influenza illness in young children, there was evidence of homosubtypic protection induced by wild-type influenza illness; however, there was no evidence of heterotypic or heterosubtypic protection. These results support previous observations that children may not develop lasting, clinically significant heterosubtypic protection after wildtype influenza infection.
